Key Highlights
- Net revenues rose 11.2% to USD 11.6 million in the third quarter ended September 30, 2026, from USD 10.4 million, with domestic core Revenue up 31.6% and international core down 16.5%.
- Gross Margin widened to 65.2% from 60.2%, and Gross Profit climbed 20.5% to USD 7.5 million on Volume growth, lower Manufacturing costs, favorable customer mix and Tariff refunds.
- Net income was USD 218,103, or USD 0.00 per share, against a net loss of USD 777,966, or USD 0.02 per share, in the prior-year quarter.
- Management raised the low end of 2026 revenue guidance to USD 48 million to USD 48.5 million, from USD 47.5 million to USD 48.5 million, and lifted its year-end cash target above USD 8 million.
Domestic Rebound Masks Slower International Shipments
KORU Medical Systems (NASDAQ:KRMD) filed its Quarterly Report on November 10, 2026 and discussed it on a call the same day. Net revenues were USD 11.6 million, up from USD 10.4 million. Domestic core revenue grew 31.6% to USD 8.1 million, though about USD 1.2 million of that reflected weak distributor orders in the prior-year quarter. International core revenue fell 16.5% to USD 3.1 million against a high comparison base. Pharma services and Clinical Trials revenue dropped 27.4% to USD 0.4 million on lower product purchases for a customer's trial. Management said normalized domestic growth was about 10% and normalized international growth was 23%.
Margin Expansion Turns the Quarter Profitable
The company makes subcutaneous infusion systems for home administration of drugs. Gross margin rose 500 basis points to 65.2%, which the filing attributed to lower manufacturing costs, higher average selling prices from geographic mix and tariff refunds of about USD 89,000. Operating expenses were USD 7.4 million, up 3.2%, as Research and Development rose 37.3% to USD 1.3 million while selling, general and administrative expense fell 2.1% to USD 5.9 million. Operating Income was USD 187,118 against an operating loss of USD 867,679. For nine months, revenue grew 17.0% to USD 35.4 million, with a net loss of USD 336,526 versus USD 2.2 million.
Raised Floor on 2026 Guidance and a Thin Cash Cushion
Management said on the call that third quarter was the trough and that it expects high-teens growth in the fourth quarter, with full-year core revenue growth of 17% to 19%. It raised the gross margin guidance floor to 63% to 64% from 62% to 64%, expects positive adjusted EBITDA for the year, and targets a year-end cash balance above USD 8 million, up from USD 7.5 million. Cash was USD 7.4 million at September 30, 2026, down from USD 8.9 million at year-end, with an unused USD 10 million Debt Facility available. Operating cash use for nine months was USD 652,054. Geographic mix is the variable management flagged as able to move margin within its range.
Where Things Stand
Possibly, but the margin gain rests partly on mix and one-time items. KORU Medical Systems (NASDAQ:KRMD) delivered 65.2% gross margin, a second straight profitable quarter and a nudge up in guidance, yet revenue growth of 11.2% was below the 17% nine-month pace, and management itself called the quarter a trough. The guided 63% to 64% full-year margin range implies some give-back, and cash of USD 7.4 million is modest. Next markers are fourth quarter revenue against the high-teens target, results from the new European and African distributors, and the year-end cash balance.






Please wait processing your request...